Renal biopsy: indications and interpretation

01Purpose and principlesWhat the assessment is for and the core concepts behind it.

Renal biopsy converts a physiological syndrome into tissue evidence. The request should state the clinical decision that rests on histology: for example, whether unexplained AKI is interstitial nephritis, whether an active nephritic sediment reflects pauci-immune vasculitis, whether nephrotic syndrome has a potentially treatable glomerular lesion, or whether chronic damage makes intensive immunosuppression unlikely to help. A biopsy performed merely because kidney function is abnormal exposes the patient to risk without a defined benefit.

The standard medical renal specimen is assessed through complementary methods. Light microscopy reveals proliferation, necrosis, crescents, sclerosis, tubular injury, interstitial inflammation, fibrosis and vascular damage. Immunofluorescence or immunoperoxidase shows immunoglobulin, complement and light-chain distribution. Electron microscopy can identify electron-dense deposits, basement-membrane ultrastructure and podocyte foot-process change. Specimen triage before fixation matters because placing all tissue in formalin can compromise some studies.

Interpretation is clinicopathological. Linear IgG staining, granular immune complexes and a pauci-immune pattern carry different implications, but serology, infection, medicines, cancer history, time course and treatment exposure determine what they mean for this patient. The final plan should identify the pathological diagnosis or differential, activity and chronicity, treatment consequence, renal prognosis and what discordance would prompt pathology review or repeat sampling.

Key points

Biopsy is justified when the likely information can alter treatment, prognosis, counselling or eligibility for a specialist therapy and the answer cannot be obtained safely by less invasive means.
Common native-kidney indications include unexplained progressive impairment, nephritic or nephrotic presentations, significant proteinuria, suspected glomerular or interstitial disease and selected systemic disorders.
The decision belongs to a renal specialist with the patient. Small kidneys, uncontrolled hypertension, bleeding disorders, a solitary kidney, obesity, frailty or inability to cooperate raise risk or reduce yield but require individual assessment rather than a memorised absolute list.
Correct reversible bleeding risk before biopsy and create a documented, indication-specific plan for every anticoagulant and antiplatelet drug; interruption may itself cause stroke, valve thrombosis or recurrent venous thromboembolism.
Ultrasound is used to choose a safe route, assess kidney size and guide the needle. Modern native biopsy is usually percutaneous and image-guided, with alternative approaches reserved for specialist circumstances.
The cortex contains glomeruli. Adequacy is not merely core length: tissue must be divided promptly and appropriately for light microscopy, immunofluorescence or immunohistology and, when needed, electron microscopy.
Read a report by compartments—glomeruli, tubules, interstitium and vessels—then separate active potentially reversible lesions from chronic scarring such as global sclerosis, tubular atrophy and interstitial fibrosis.
Immunofluorescence describes immune deposits and their location; electron microscopy resolves basement membranes, podocyte foot processes and small deposits. Neither should be interpreted without light microscopy and clinical serology.
A biopsy diagnosis is a sample from one time and place. Focal disease can be missed, treatment can modify appearances and chronic damage may limit the value of aggressive immunosuppression despite a named diagnosis.
Bleeding is the principal procedural complication. UK Kidney Association NEPHwork audit data recorded complications in 5.8% and major complications in 1.9% of 1,713 native biopsies, reinforcing the need for consent and post-procedure surveillance.

02Indications, selection and cautionsWhen it is useful, when urgency changes and important limitations.

Rapidly progressive nephritic syndromeRed flag

A rapid creatinine rise with haematuria, proteinuria, red-cell casts, hypertension and systemic vasculitic or pulmonary features suggests active crescentic disease. Urgent serology and nephrology discussion run in parallel with expedited biopsy planning.

Nephrotic presentationRed flag

Heavy protein loss, hypoalbuminaemia and oedema can arise from primary glomerular disease, diabetes, amyloid, lupus, medicines or malignancy. Histology is often important in adults when a non-invasive diagnosis is not secure.

Unexplained intrinsic AKIRed flag

Persistent renal decline after perfusion and obstruction are addressed, especially with pyuria, eosinophilia, haematuria or drug exposure, raises tubular, interstitial or glomerular disease for which tissue may change management.

Systemic or monoclonal diseaseRed flag

Lupus features, vasculitis, chronic infection, paraprotein, amyloid phenotype or complement disturbance may require biopsy to classify renal involvement and assess irreversible damage before hazardous treatment.

High bleeding-risk phenotype

Uncontrolled blood pressure, thrombocytopenia or coagulopathy, antithrombotic treatment, anaemia, advanced dysfunction, a single kidney, technical difficulty or inability to follow breathing instructions changes the route, timing or suitability.

Post-biopsy haemorrhageRed flag

New severe flank or abdominal pain, tachycardia, hypotension, visible blood, reduced urine from clots, presyncope or haemoglobin fall can indicate perinephric or urinary bleeding and needs prompt imaging and senior escalation.

03Method and interpretationA systematic approach to the test and its findings.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
FBC, coagulation screen and blood group testingFirst step
Why
Identify anaemia, thrombocytopenia or coagulation abnormality and prepare for haemorrhage according to procedural policy.
Interpretation and limitations
A normal basic screen does not quantify every antiplatelet or anticoagulant effect. Correct abnormalities and confirm drug timing with haematology or peri-procedural guidance when risk is complex.
02
Renal profile and serial eGFR trend
Why
Define acuity, biochemical danger and the potential diagnostic value of tissue before intervention.
Interpretation and limitations
Advanced dysfunction increases procedural and treatment complexity. A dynamic creatinine invalidates steady-state eGFR as an exact measure, but the trajectory remains central to urgency.
03
Urine ACR or PCR with sediment microscopy
Why
Quantify the presenting syndrome and identify glomerular features that make biopsy more informative.
Interpretation and limitations
Protein magnitude and dysmorphic red cells or casts help frame the question but do not specify histology. Bland urine does not exclude interstitial, vascular or paraprotein disease.
04
Targeted serology and monoclonal-protein assessment
Why
Provide pre-test diagnoses and ensure pathology performs appropriate stains or ultrastructural work.
Interpretation and limitations
Select ANCA, anti-GBM, ANA or dsDNA, complement, immunoglobulins, electrophoresis, immunofixation and free light chains from the phenotype; positive results still need clinical correlation.
05
Pre-biopsy renal ultrasound
Why
Confirm anatomy, size, location, cysts and a feasible image-guided route.
Interpretation and limitations
Small echogenic kidneys suggest chronic scarring and reduced yield but are not the sole decision. A solitary kidney or difficult body habitus prompts expert route and benefit-risk review.
06
Light microscopy
Why
Assess the architecture and cellular lesions across glomerular, tubulointerstitial and vascular compartments.
Interpretation and limitations
Describe active changes such as necrosis, crescents or interstitial inflammation separately from global sclerosis, tubular atrophy and fibrosis. Sampling adequacy limits confidence in focal disease.
07
Immunofluorescence or immunohistology
Why
Localise immunoglobulins, complement and light chains and distinguish linear, granular and pauci-immune patterns.
Interpretation and limitations
Intensity and distribution must match clinical serology and light microscopy. Trapping in scarred areas is not equivalent to a disease-defining deposit pattern.
08
Electron microscopy
Why
Resolve deposits, basement membranes, podocyte foot processes and inclusions below light-microscopy resolution.
Interpretation and limitations
Diffuse foot-process effacement supports podocyte injury but is not a stand-alone aetiology. Electron-dense deposit location refines, rather than replaces, the integrated diagnosis.

04Clinical next stepsHow the result changes management or prompts escalation.

01DecisionConfirm that tissue will change careFirst stepA renal syndrome remains unexplained after initial blood, urine and imaging assessment.

1Construct a narrow differential from acuity, eGFR trajectory, protein loss, sediment, serology, medicines and systemic features, and state the unresolved management decision.
2Discuss with nephrology whether tissue is likely to distinguish actionable diagnoses or quantify activity and chronicity better than non-invasive tests.
3Explain alternatives, the possibility of a non-diagnostic sample, bleeding risk and how each plausible result would change therapy before obtaining consent.

02PreparationReduce modifiable procedural riskA specialist decision has been made to proceed with native renal biopsy.

1Confirm indication, anatomy, observations, haemoglobin, platelets, coagulation, renal profile, pregnancy status where relevant and an appropriate image-guided operator and environment.
2Reconcile prescribed and non-prescribed antithrombotic medicines and agree stop, bridging if ever indicated, and restart timing with the renal unit and original specialty; control blood pressure to the local threshold.
3Coordinate pathology specimen requirements in advance, obtain informed consent and document post-procedure observation duration, transport, activity and emergency-contact instructions.

03InterpretationBuild the clinicopathological diagnosisA preliminary or final renal pathology report becomes available.

1Check sample adequacy and which modalities were performed, then extract glomerular, tubular, interstitial and vascular findings rather than relying only on the headline label.
2Map immune pattern, electron-microscopy findings, activity and chronicity against serology, infection screen, drug exposure, paraprotein testing and tempo.
3Agree treatment and prognosis in nephrology-pathology discussion when discordant or high stakes, and explain what is known, uncertain and monitored to the patient.

04ComplicationRespond to post-biopsy bleedingPain, haemodynamic change, gross haematuria, oliguria or haemoglobin fall after the procedure.

1Perform ABCDE, obtain IV access, repeat FBC and coagulation, group and save or crossmatch, examine the biopsy side and quantify urinary bleeding and output.
2Alert the renal procedural team and obtain urgent imaging selected with radiology, usually ultrasound or CT angiographic assessment according to stability and suspected active bleeding.
3EscalationResuscitate and correct coagulopathy without losing sight of thrombotic indication; escalate persistent arterial bleeding for interventional radiology embolisation and involve surgery or urology when required.

05Procedure and medicine safetyRelevant preparation, treatment and contraindications.

Reduces preventable biopsy haemorrhage while maintaining a safe plan for stroke, valve or venous thromboembolism prevention.

Anticoagulant and antiplatelet peri-biopsy plan

Do not apply a universal interval. The renal unit sets last dose and restart from the exact agent, renal clearance, indication, thrombotic risk, bleeding risk and procedural route.

Stopping without agreement can be catastrophic, and routine heparin bridging may increase bleeding. Renal impairment prolongs some agents; document who authorises both interruption and resumption.

Provides non-NSAID analgesia for expected mild puncture-site discomfort.

Paracetamol after uncomplicated biopsy

Use the locally approved adult regimen, reduced where low body weight, liver disease, malnutrition or other paracetamol-containing products require it.

Severe or escalating pain is not an indication for repeated analgesia alone; reassess for bleeding. Avoid inadvertent duplicate paracetamol products and review persistent pain.

Supports resuscitation and corrects contributory anticoagulant or coagulation abnormalities during serious post-biopsy haemorrhage.

Blood components or haemostatic reversal

Use only for clinically significant bleeding or a defined defect under the major-haemorrhage, haematology and agent-specific reversal pathway.

Treatment is not prophylactic for every patient and carries thrombosis, transfusion and volume risks. Do not delay embolisation when active arterial bleeding persists.

06Risks, monitoring and follow-upComplications, safety checks and further assessment.

Before biopsy, recheck blood pressure and verify that laboratory results and antithrombotic timings remain within the renal unit's current procedural limits.
After biopsy, follow pulse, blood pressure, pain score, puncture site and urine appearance at the local observation frequency, with longer surveillance when risk is higher.
Repeat haemoglobin or imaging when symptoms, observations or the local protocol indicate; a reassuring immediate reading does not override a deteriorating clinical picture.
Give written advice about visible haematuria, severe loin pain, dizziness, fever, reduced urine and activity or lifting restrictions, with a direct route back to urgent care.
Track the pathology sample through preliminary and final reporting, including immunofluorescence and electron microscopy addenda, so treatment is not based on an incomplete report.
After the diagnostic meeting, monitor the chosen disease markers—eGFR, ACR or PCR, sediment, blood pressure, serology and drug toxicity—at intervals matched to activity.

07Special situationsVariants, exceptions and circumstances that change the usual approach.

A biopsy answers a verb

The strongest indication is not 'CKD' but a decision such as classify, confirm, stage activity, estimate reversibility or select treatment. This exposes tests unlikely to improve care.

Cortex is the target

Glomeruli lie in cortex, so a core composed mainly of medulla may be long yet diagnostically poor for glomerular disease. Adequacy is diagnosis-specific.

Activity and chronicity coexist

Cellular crescents or active interstitial inflammation may sit beside global sclerosis and fibrosis. The balance helps judge both urgency and realistic renal recovery.

Pauci-immune is a staining description

Little immunoglobulin deposition supports a vasculitic mechanism in the right setting, but ANCA status, infection, drug exposure and clinical phenotype still shape the final diagnosis.

The sample can miss focal disease

Focal segmental lesions and patchy vasculitis may not appear in a limited core. Strong clinicopathological discordance merits review of levels, modalities and sometimes repeat tissue.

Complication numbers aid consent

NEPHwork's national audit gives contemporary UK context, but an individual's risk depends on blood pressure, kidney function, haemoglobin, coagulation, anatomy and procedural expertise.

08Common pitfallsFrequent interpretation and management errors.

01
Requesting biopsy for an undifferentiated creatinine rise before excluding obstruction, haemodynamic causes and medication effects.
02
Calling a small or solitary kidney an automatic absolute contraindication without specialist benefit-risk assessment.
03
Stopping anticoagulation from a generic table without considering renal clearance and the original thrombotic indication.
04
Sending every core in one fixative and losing the opportunity for optimal immunofluorescence or electron microscopy.
05
Treating the pathology headline as complete while ignoring sample adequacy, activity, chronicity and compartment details.
06
Reassuring a patient with severe post-biopsy loin pain because the first urine sample is clear.
07
Starting high-risk immunosuppression without reconciling histology with infection, malignancy and serological evidence.